Results 11 to 20 of about 41,957 (263)
Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL [PDF]
Background: Recently, it was reported that leucine-rich repeat-containing G-protein-coupled receptor 4 (LGR4, also called GPR48) is another receptor for RANKL and was shown to compete with RANK to bind RANKL and suppress canonical RANK signaling during osteoclast differentiation.
Yuria Jang +4 more
openaire +2 more sources
Receptor activator of nuclear factor κB (RANK) and its ligand (RANKL) have originally been described for their key roles in bone metabolism and the immune system. Subsequently, it has been shown that the RANKL-RANK system is critical in the formation of mammary epithelia in lactating females and the thermoregulation of the central nervous system. RANKL
Vanja, Nagy, Josef M, Penninger
openaire +2 more sources
Targeting RANKL in metastasis [PDF]
Acting through its cognate receptor, receptor activator of nuclear factor-κB (RANK), RANK ligand (RANKL) is an essential mediator of osteoclast function and survival. Preclinical data have now firmly established that blockade of tumor-induced osteoclastogenesis by RANKL inhibition will not only protect against bone destruction but will also inhibit the
Dougall, W.C. +2 more
openaire +4 more sources
OSTEOPROTEGERIN, RANK, RANKL [PDF]
Osteoprotegerin, RANK (Receptor Activator of Nuclear factor kappa B) and RANKL (Receptor Activator of Nuclear faktor kappa B ligand) became the aim of intensive research. RANK is considered as a hematopoietic surface receptor controlling osteoclastogenesis and calcium metabolism.
D, Stejskal +5 more
openaire +2 more sources
Osteopetrosis rescue upon RANKL administration to Rankl−/− mice: A new therapy for human RANKL-dependent ARO [PDF]
Abstract In the last decades the molecular basis of monogenic diseases has been largely unraveled, although their treatment has often remained unsatisfactory. Autosomal recessive osteopetrosis (ARO) belongs to the small group of genetic diseases that are usually treated with hematopoietic stem cell transplantation (HSCT).
LO IACONO N +21 more
openaire +2 more sources
Given the increasing risk of fractures with aging in western countries, there is a need for the development of safe and efficient anti-osteoporotic drugs for the prevention and treatment of osteoporosis. Recent studies have provided evidence for an essential role of RANKL (Receptor Activator of Nuclear Factor-kappa B Ligand) and its decoy receptor ...
Pierre Marie, Philippe Halbout
openaire +1 more source
RANK–RANKL signalling in cancer [PDF]
Oncogenic events combined with a favourable environment are the two main factors in the oncological process. The tumour microenvironment is composed of a complex, interconnected network of protagonists, including soluble factors such as cytokines, extracellular matrix components, interacting with fibroblasts, endothelial cells, immune cells and various
Heymann, D. +4 more
openaire +3 more sources
Osteoclast activity in osteoporosis mandibular bone based on RANKL and osteoprotegerin ratio. [PDF]
Context: Osteoporosis occurs not only in the lumbar bone, femur, and radius but also occurs in the mandibular bone. Therefore, osteoporosis is a disease that required attention from the dentists.
Mefina Kuntjoro +5 more
doaj
Regulation of neurite growth by tumour necrosis superfamily member RANKL [PDF]
RANKL (receptor-activator of NF-κB ligand, TNFSF11) is a member of the TNF superfamily that regulates bone remodelling and the development of the thymus, lymph nodes and mammary glands.
Humberto Gutierrez +5 more
doaj +1 more source
Objective To investigate the mechanisms of 1, 25(OH)2D3 on joint inflammation and bone destruction in a mouse model of collagen-induced arthritis (CIA). Methods Thirty DBA/1J mice were equally allocated into control, CIA and intervention (VD) groups. The
QI Kun, LIU Yun, TANG Tao, LUO Xiwen
doaj +1 more source

